Pharmacy Medical News about Economic Costs

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Distinguishing the Economic Costs Associated with Type 1 and Type 2 Diabetes
Population Health Management, 04/27/09

Dall TM et al. - The prevalence of T2DM is significantly greater than the prevalence of T1DM, so T2DM is responsible for most of the economic burden of diabetes. Estimates for T1DM are sensitive to the criteria used to identify people with diabetes using claims data; estimates for T2DM are relatively stable. Improved coding of diabetes type in medical claims and identification of diabetes type in survey data could lead to more precise estimates of the economic burden by diabetes type.

<< Previous
Development of Parkinsonism following exposure to aripiprazole

Next >>
Does income-related health inequality change as the population...

The Impact of Differences in EQ-5D and SF-6D Utility Scores on the Acceptability of Cost–Utility Ratios: Results across Five Trial-Based Cost-Utility Studies
Value in Health, 11/11/09 Relevance Score: 68%

Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation
Annals of Internal Medicine, 11/04/09 Relevance Score: 68%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09 Relevance Score: 67%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09 Relevance Score: 67%

Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
PharmacoEconomics, 10/07/09 Relevance Score: 67%